Tirzepatide is a new class of medication for t2d that activates GIP and glp1 receptors. Endocrinologist Dr. Thomas Blevins (MD, FACE) from Texas Diabetes and Endocrinology, Austin, TX, presents data and practical information for clinicians.
Tirzepatide Once Weekly for the Treatment of Obesity (2022) Ania M. Jastreboff, M.D., Ph.D., Louis J. Aronne, M.D., Nadia N. Ahmad, M.D., M.P.H., Sean Wharton, M.D., Pharm.D., Lisa Connery, M.D., Breno Alves, M.D., Arihiro Kiyosue, M.D., Ph.D., Shuyu Zhang, M.S., Bing Liu, Ph.D., Mathijs C...
Here are the key points from the video titled "Once-Weekly Tirzepatide for Obesity | NEJM": Study Objective: The trial investigated the effectiveness of the type 2 diabetes drug, tirzepatide, in inducing weight reduction in adults with obesity or overweight plus a weight-related complication...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.